

Prior Authorization Request Form Fax Back To: (866) 940-7328

Phone: (800) 310-6826

## **Specialty Medication Prior Authorization Cover Sheet**

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to <a href="https://www.uhcprovider.com">www.uhcprovider.com</a> for medication fax request forms.)

Patient's Name:							
Insurance ID: Date of Birth: Height: Weight:							
Address: Apartment #:							
City: State: Zip Code:							
Phone Number: Alternate Phone: Sex: Male Fema	le						
Provider Information							
Provider's Name: Provider ID Number:							
Address: City: State: Zip Code:							
Suite Number: Building Number:							
Phone Number: Fax number:							
Provider's Specialty:							
Medication Information							
Medication: Quantity: ICD10 Code:							
Directions: Diagnosis: Refills:							
Physician Signature**: Initial here if DAW:							
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.							
Medication Instructions							
Has the patient been instructed on how to <b>Self-Administer</b> ? ☐ Yes ☐ No							
Is this medication a <b>New Start</b> ?							
If continuation please provide the following: Initiation Date: / / Date of Last Dose: / /							
Is there documentation of positive clinical response to current therapy?							
**Please attach any pertinent clinical information that would pertain to support stated diagnosis.  Additional clinical information may be needed depending on your patients plan, including medication(s) previously tried and failed.							
Delivery Instructions							
Delivery instructions	Note: Delivery coordination requires a "Physician Signature" above <u>and complete</u> "Provider Information" <u>and</u> "Patient Information"  Note: All necessary ancillary supplies are provided free of charge to the patient at the time of delivery						
Note: Delivery coordination requires a "Physician Signature" above and complete "Provider Information" and "Patient Information"							
Note: Delivery coordination requires a "Physician Signature" above and complete "Provider Information" and "Patient Information"							



## Xalkori - Washington

## PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A - Member Inforn	nation						
First Name:	Last Name:				Member ID:		
Address:							
City:		State:			ZIP Code:		
Phone:	e: DOB:				Allergies:		
Primary Insurance Information:				,			
Is the requested medication	n 🗆 New or 🗆 C	Continuation	on of Therapy? If c	ontinuation, list	start date:		
Is this patient currently hos	-	Yes □ No	If recently discha	rged, list discha	arge date: _		
Section B - Provider Inform	nation		Last Name:			M D /D O	
First Name:					01.1.	M.D./D.O.	
Address:			City:		State:	ZIP code:	
Phone:	Fax:		NPI #:		Specialty:		
Office Contact Name / Fax a	ttention to:						
Section C - Medical Inform Medication:	ation				Strength	:	
Directions for use:					Quantity	:	
Diagnosis (Please be speci	fic & provide as	much info	rmation as possible)	:	ICD-10 (	CODE:	
Is this member pregnant?	□ Yes □ No	If yes	s, what is this mem	ber's due date?			
Section D - Previous Medi	cation Trials						
	cation Trials	If yes	o, what is this mem	ber's due date?  Dates of The	rapy Re	eason for failure /	
Section D - Previous Medi	cation Trials				rapy Re		
Section D - Previous Medi	cation Trials				rapy Re		
Section D - Previous Medi	cation Trials				rapy Re		
Section D - Previous Medi	cation Trials				rapy Re		
Section D – Previous Medinations	cation Trials Stre	ngth	Directions	Dates of The	rapy Re	discontinuation	
Section D – Previous Medinal Medications  Section E – Additional infor	cation Trials Stre	ngth	Directions	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications  Section E – Additional infor	cation Trials Stre	ngth	Directions  of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications  Section E – Additional infor	cation Trials Stre	ngth	Directions  of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications  Section E – Additional infor	cation Trials Stre	ngth	Directions  of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications  Section E – Additional infor	cation Trials Stre	ngth	Directions  of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications  Section E – Additional infor	cation Trials Stre	ngth	Directions  of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications  Section E – Additional infor	cation Trials Stre	ngth	Directions  of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications  Section E – Additional infor	cation Trials Stre	ngth	Directions  of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications  Section E – Additional infor	cation Trials Stre	ngth	Directions  of why preferred m	Dates of The	rapy Re	the patient's needs:	



**Physician Signature:** 

## Xalkori - Washington

PRIOR AUTHORIZATION REQUEST FORM

Date:

Member First name:		Member Last name:	Member DOB:					
Clinical and Drug Specific Information								
ALL REQUESTS								
□ Yes □ No	Does the patient have any of the following diagnoses? (If yes, check which applies)  □ Inflammatory Myofibroblastic Tumor (IMT) with ALK translocation							
□ Yes □ No	Is the use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium?  If yes, list supported use:							
		NSCLC						
□ Yes □ No	Is the patient's disease any of the following? (If yes, check which applies)  □ Metastatic □ Recurrent							
□ Yes □ No	Does the patient have any of the following? (If yes, check which applies)  □ Tumor is anaplastic lymphoma kinase (ALK)-positive  □ Tumor is ROS1-positive  □ Tumor is positive for mesenchymal-epithelial transition (MET) amplification  □ Tumor is positive for MET exon 14 skipping mutation							
	<u> </u>	CNS CANCER						
□ Yes □ No	Is the tumor one of the following? (If yes, check which applies)  □ Anaplastic lymphoma kinase (ALK)-positive □ ROS1-positive							
ANAPLASTIC LARGE CELL LYMPHOMA								
□ Yes □ No	Is the tumor ROS1-posit							
□ Yes □ No	Is the disease relapsed or refractory?  If yes, list response:							
CONTINUATION OF THERAPY								
□ Yes □ No	•	vidence of progressive disease while o						
□ Yes □ No	Does the patient have a documented positive clinical response to Xalkori therapy?  If yes, list response:							

**Confidentiality Notice:** This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.